Astrazeneca

FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (68)Koselugo approved in the US for adults with neurofibromatosis type 1
Preheader (68)Koselugo approved in the US for adults with neurofibromatosis type 1
Typography
Arial
Colors
Text Analysis
Body Words112
Subject Words11
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px690 px
X-Spam Score-0.1
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeOvernight

Koselugo approved in the US for adults with neurofibromatosis type 1

Koselugo approved in the US for adults with neurofibromatosis type 1
Koselugo approved in the US for adults with neurofibromatosis type 1